Dalpiciclib is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor primarily used in the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-)… Read more
Dalpiciclib is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor primarily used in the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. This category provides essential reference standards for Dalpiciclib, including stable isotope labelled compounds such as Dalpiciclib-d4, which serve as high-precision internal standards for mass spectrometry-based analytical testing. It also includes a range of critical impurity standards, such as N1-nitroso, N2-nitroso, and N1,N2-diitroso derivatives, which are vital for impurity profiling, method validation, and ongoing quality control during pharmaceutical development. These materials support laboratories in ensuring the accurate quantification and characterization of the drug and its related substances, facilitating rigorous compliance with analytical standards and consistency in stability testing protocols throughout the drug lifecycle.